Industry Growth Insights published a new data on “Genetic Virus Vector Market”. The research report is titled “Genetic Virus Vector Market research by Types (Retroviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Other), By Applications (Gene Therapy, Vaccinology), By Players/Companies FUJIFILM Diosynth Biotechnologies U.S.A., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., Kaneka Eurogentec S.A.”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Genetic Virus Vector Market Research Report
By Type
Retroviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Other
By Application
Gene Therapy, Vaccinology
By Companies
FUJIFILM Diosynth Biotechnologies U.S.A., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., Kaneka Eurogentec S.A.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
144
Number of Tables & Figures
101
Customization Available
Yes, the report can be customized as per your need.
Global Genetic Virus Vector Market Report Segments:
The global Genetic Virus Vector market is segmented on the basis of:
Types
Retroviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Gene Therapy, Vaccinology
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- FUJIFILM Diosynth Biotechnologies U.S.A.
- Sanofi
- Lonza
- Merck KGaA
- GENERAL ELECTRIC COMPANY
- Oxford BioMedica
- Spark Therapeutics, Inc.
- uniQure N.V.
- FinVector Vision Therapies
- Brammer Bio
- Cell and Gene Therapy Catapult
- Cobra Biologics
- REGENXBIO Inc.
- Kaneka Eurogentec S.A.
Highlights of The Genetic Virus Vector Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Retroviral Vectors
- Adenoviral Vectors
- Adeno-Associated Viral Vectors
- Other
- By Application:
- Gene Therapy
- Vaccinology
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Genetic Virus Vector Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A genetic virus vector is a type of virus that uses the genetic material of other viruses to replicate. This can be done by either injecting the viral genes directly into cells or by using a vector, such as a bacterium, to transport the viral genes into cells.
Some of the key players operating in the genetic virus vector market are FUJIFILM Diosynth Biotechnologies U.S.A., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., Kaneka Eurogentec S.A..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Genetic Virus Vector Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Genetic Virus Vector Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Genetic Virus Vector Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Genetic Virus Vector Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Genetic Virus Vector Market Size & Forecast, 2018-2028
4.5.1 Genetic Virus Vector Market Size and Y-o-Y Growth
4.5.2 Genetic Virus Vector Market Absolute $ Opportunity
Chapter 5 Global Genetic Virus Vector Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Genetic Virus Vector Market Size Forecast by Type
5.2.1 Retroviral Vectors
5.2.2 Adenoviral Vectors
5.2.3 Adeno-Associated Viral Vectors
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Genetic Virus Vector Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Genetic Virus Vector Market Size Forecast by Applications
6.2.1 Gene Therapy
6.2.2 Vaccinology
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Genetic Virus Vector Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Genetic Virus Vector Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Genetic Virus Vector Analysis and Forecast
9.1 Introduction
9.2 North America Genetic Virus Vector Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Genetic Virus Vector Market Size Forecast by Type
9.6.1 Retroviral Vectors
9.6.2 Adenoviral Vectors
9.6.3 Adeno-Associated Viral Vectors
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Genetic Virus Vector Market Size Forecast by Applications
9.10.1 Gene Therapy
9.10.2 Vaccinology
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Genetic Virus Vector Analysis and Forecast
10.1 Introduction
10.2 Europe Genetic Virus Vector Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Genetic Virus Vector Market Size Forecast by Type
10.6.1 Retroviral Vectors
10.6.2 Adenoviral Vectors
10.6.3 Adeno-Associated Viral Vectors
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Genetic Virus Vector Market Size Forecast by Applications
10.10.1 Gene Therapy
10.10.2 Vaccinology
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Genetic Virus Vector Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Genetic Virus Vector Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Genetic Virus Vector Market Size Forecast by Type
11.6.1 Retroviral Vectors
11.6.2 Adenoviral Vectors
11.6.3 Adeno-Associated Viral Vectors
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Genetic Virus Vector Market Size Forecast by Applications
11.10.1 Gene Therapy
11.10.2 Vaccinology
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Genetic Virus Vector Analysis and Forecast
12.1 Introduction
12.2 Latin America Genetic Virus Vector Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Genetic Virus Vector Market Size Forecast by Type
12.6.1 Retroviral Vectors
12.6.2 Adenoviral Vectors
12.6.3 Adeno-Associated Viral Vectors
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Genetic Virus Vector Market Size Forecast by Applications
12.10.1 Gene Therapy
12.10.2 Vaccinology
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Genetic Virus Vector Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Genetic Virus Vector Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Genetic Virus Vector Market Size Forecast by Type
13.6.1 Retroviral Vectors
13.6.2 Adenoviral Vectors
13.6.3 Adeno-Associated Viral Vectors
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Genetic Virus Vector Market Size Forecast by Applications
13.10.1 Gene Therapy
13.10.2 Vaccinology
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Genetic Virus Vector Market: Competitive Dashboard
14.2 Global Genetic Virus Vector Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 FUJIFILM Diosynth Biotechnologies U.S.A.
14.3.2 Sanofi
14.3.3 Lonza
14.3.4 Merck KGaA
14.3.5 GENERAL ELECTRIC COMPANY
14.3.6 Oxford BioMedica
14.3.7 Spark Therapeutics, Inc.
14.3.8 uniQure N.V.
14.3.9 FinVector Vision Therapies
14.3.10 Brammer Bio
14.3.11 Cell and Gene Therapy Catapult
14.3.12 Cobra Biologics
14.3.13 REGENXBIO Inc.
14.3.14 Kaneka Eurogentec S.A.
